2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.32: A Real-World Study of the Efficacy and Safety of Anlotinib Monotherapy or Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer

PP02.32: A Real-World Study of the Efficacy and Safety of Anlotinib Monotherapy or Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study examines the real-world efficacy and safety of anlotinib, administered either as a standalone treatment or in combination with other therapies, in patients with advanced non-small cell lung cancer (NSCLC) in China. Anlotinib is a tyrosine kinase inhibitor that targets specific receptors, and while clinical trials have shown its potential, many patients do not fit the standard trial criteria, necessitating this real-world study.<br /><br />The research, conducted from February 2020 to November 2023, involved NSCLC patients treated with anlotinib-based therapies. Efficacy was assessed using the RECIST version 1.1 criteria, and key indicators included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Safety was evaluated based on the occurrence of adverse events (AEs).<br /><br />Participants had a median age of 68, with some presenting brain (11%) and liver (14%) metastases. Anlotinib was used in the first line for 13% of patients, second line for 33%, and third line or beyond for 20%. Combination therapies included chemotherapy, targeted therapy, and immunotherapy. Results showed a median PFS of 7.5 months, ORR of 39%, and DCR of 84%. Adverse events were reported in 66% of patients, with grade 3 or higher in 50%. Importantly, there were no serious infections, treatment-related deaths, or unexpected AEs, and no patient discontinued due to toxicity.<br /><br />In conclusion, anlotinib showed significant efficacy and a manageable safety profile, affirming its role in treating advanced NSCLC either alone or in combination with other treatments. This study supports the wider application of anlotinib beyond controlled trial environments, providing valuable insights for clinical practice.

Asset Subtitle

Di Zheng

Keywords

anlotinib

NSCLC

real-world study

tyrosine kinase inhibitor

progression-free survival

objective response rate

disease control rate

adverse events

combination therapy

clinical practice